Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

Figure 7

Distant-metastasis-free survival (DMFS) and Breast-cancer-specific survival (BCSS) according to the serum HER2 ECD level by the lower cutoffs and the early stages. (A) DMFS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)] in breast cancer patients with stage I and II. (B) BCSS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)] in breast cancer patients with stage I and II (C) DMFS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in breast cancer patients with stage I and II (D) BCSS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in breast cancer patients with stage I and II (E) DMFS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)] in breast cancer patients with stage I, II and III (F) BCSS according to serum HER2 ECD level [elevated level (>10.2 ng/ml) vs normal level (≤10.2 ng/ml)] in breast cancer patients with stage I, II and III (G) DMFS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in breast cancer patients with stage I, II and III (H) BCSS according to serum HER2 ECD level [elevated level (>7.7 ng/ml) vs normal level (≤7.7 ng/ml)] in breast cancer patients with stage I, II and III.

Back to article page